The Johns Hopkins University researchers behind two of Baltimore’s most successful biotech firms have founded a new company that has now raised $56 million to create a new diagnostic tool for cancer.
The University of Maryland is partnering with Montgomery County to develop a new biotech campus near the North Bethesda Metro Station that will open in 2023.
The new facility will be yet another biotech stakeholder in the county, which is one of the richest biotech hubs in the nation. The university’s campus will join federal research laboratories, including the National Institutes of Health and the Food and Drug Administration, and significant private sector companies such as GSK plc and AstraZeneca.
The new campus, named the University of Maryland 3 — Institute for Health Computing, will focus on life sciences research.
The institute is scheduled to open at a temporary location in the first half of 2023 before moving to a permanent location by 2028 near the North Bethesda Metro Station, according to Tom Lewis, who is leading the project.
While the exact specifications are being finalized, Lewis expects the campus to be between 20,000 and 25,000 square feet. The campus will begin with about 20 employees before scaling up to almost 100 employees in 18 months.
Click here to read more via the Diamondback
Decades of Experience and Emerging Opportunities Led to its Creation
ROCKVILLE, Md., Dec. 8, 2022 /PRNewswire/ — Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced the creation of a dedicated center to enhance Emmes’ legacy and depth in cell and gene therapy research.
The new center will focus on supporting the clinical trials of our clients who are developing cell and gene therapies around the world and across multiple therapeutic areas, including hematology, oncology, cardiology and ophthalmology, as well as rare diseases. The center will combine a team of 100 researchers to capitalize on the company’s 35 years of cell and gene therapy experience.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., December 08, 2022–(BUSINESS WIRE)–United Therapeutics (Nasdaq: UTHR), a public benefit corporation, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2023. This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The list of awards was announced on December 7, 2022, is available on Newsweek’s website, and recognizes the top 500 most responsible companies in the United States, spanning 14 industries.
- Emergent’s supplemental new drug application is the first prescription-to-over-the-counter switch application in history to be granted Priority Review by the FDA.
- NARCAN® (naloxone HCI) Nasal Spray 4 mg, the first intranasal form of naloxone approved by the FDA in 2015, is designed for community use for the treatment of known or suspected opioid overdose.
GAITHERSBURG, Md., Dec. 06, 2022 (GLOBE NEWSWIRE) — Today, Emergent BioSolutions Inc. (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) for NARCAN® (naloxone HCI) Nasal Spray, as an over-the-counter (OTC) emergency treatment for known or suspected opioid overdose. The application has been granted Priority Review by the FDA and, if approved, would be the first 4 mg naloxone nasal spray available OTC in the U.S. The Prescription Drug User Fee Act goal date is March 29, 2023.
The opioid epidemic is an ongoing national public health issue and has been exacerbated by the escalating use of synthetic opioids, namely fentanyl. According to the Centers for Disease Control and Prevention, deaths related to synthetic opioids increased nearly 60 percent from 2019 to 2020,1 and in 2021 alone, more than 71,000 people died from opioids containing fentanyl.2
University of Maryland College Park (UMCP) graduates are some of the most sought-after graduates in the country – Maryland is the No. 1 state for technology and science workforce and second in graduate or professional degree attainment. The state is also the second-largest recipient of federal funding in Maryland and 10th in the nation among public universities, according to Ken Porter, director of UM Ventures for UMCP.
UMCP is one of five universities working in partnership with TEDCO as part of our Maryland Innovation Initiative (MII), established in 2012 as a technology transfer program with the goal to grow and accelerate promising technologies through venture creation. Porter is a member of the MII board.
WASHINGTON, Dec. 2, 2022 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase II clinical study of VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist, in the treatment of acute performance anxiety in social situations, such as public speaking.
In clinical study VP-VQW-765-2201 (Study 2201), 230 volunteers with prior history of performance anxiety were randomized to receive a single dose of VQW-765 or placebo and were challenged with the standardized Trier Social Stress Test (TSST). The TSST creates an acute stress by requiring participants to make an interview-style presentation in front of a panel who provides no feedback or encouragement. Participants who received VQW-765 showed numerically lower stress levels compared to those who received placebo.
3D Model of ATP Synthase – molecular motor (enzyme) that powers cells, generating chemical energy in the form of ATP molecules.
The 1997 Nobel prize in Chemistry was awarded to John Walker and Paul Boyer for solving the structure and mechanism of the enzyme ATP synthase which is involved in the synthesis of adenosine triphosphate (ATP). ATP is a molecule that provides energy to drive many processes in living cells.
Join Venable’s Ari J. Markenson, Ilisa Halpern Paul, and Joshua Raymond in a discussion of the implications for national healthcare and life sciences policy following the results of the midterm congressional election. Ari will moderate the discussion with Ilisa and Joshua as they provide insights into and analysis of what investors, lenders, providers, manufacturers, and stakeholders might expect in the next 18 to 24 months with respect to federal health policy. The discussion will cover a wide range of topics, such as the anticipated House and Senate policy agendas, regulatory priorities for the Biden-Harris administration, and potential areas of bipartisan agreement. There will be time for questions from the audience following the panel.
Maryland Manufacturing Extension Partnership joins City/County consortium to expand third Biotech Bootcamp in Frederick
FREDERICK, MD. (PRWEB) DECEMBER 01, 2022
Following the completion of two successful sessions, Frederick Community College, Frederick County Workforce Services, The City of Frederick Department of Economic Development, and the Frederick County Office of Economic Development are pleased to announce the next “Biotech Bootcamp” will be held in Frederick in January 2023. Maryland Manufacturing Extension Partnership (Maryland MEP) has joined the Frederick consortium to provide additional programming support aimed at expanding the program’s footprint in the future.